Global Factor VIII Deficiency Treatment Market: Key Developments
In November 2022, the U.S. Food and Drug Administration announced that they have approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia A and B (congenital Factor IX and/or VIII deficiency)
In December 2021, Pfizer Inc., a U.S.-based multinational biopharmaceutical company, and Sangamo Therapeutics, Inc., a genomic medicines company, announced that their drug candidate giroctocogene fitelparvovec an investigational gene therapy for patients with moderately severe to severe hemophilia A, meet the regulatory requirements.
Global Factor VIII Deficiency Treatment Market: Key Players
Major players operating in the Global Factor VIII Deficiency Treatment market include Baxter, Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S
Global factor VIII deficiency treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients